Hot Debate: Complement Inhibition vs Nefecon in IgA Nephropathy – Which First for Patients at Risk? - International Society of Nephrology Events

Magdalena Madero Moderator Mexico

Time	Session

2:10 p.m. 3:10 p.m.	Complement Inhibition Should Be Considered Before Nefecon in Patients With IgAN at Risk of Progression VladoPerkovic Speaker Australia	Nefecon Should Be Considered Before Complement Inhibition in Patients With IgAN at Risk of Progression HongZhang Speaker China